Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFAMOSI
DRKS00020509Phase 4Terminated
- Sponsor
- University Medical Center Mainz
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of afatinib and osimertinib in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by University Medical Center Mainz. Started Jun 2020; status: terminated.
02
Drugs
afatinibosimertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on DRKS00020509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00020509.